Serum anti-p53 antibody is used clinically as a tumor marker of colorectal cancer. However, its prognostic significance in patients with metastatic colorectal cancer (mCRC) remains unclear. KRAS status may influence the host immune response against tumor progression. In the present study, we investigated the prognostic significance of serum anti-p53 in mCRC patients with wild-type KRAS and mutant KRAS treated with systemic chemotherapy.

中文翻译：

---

根据KRAS状况，血清p53抗体对转移性结直肠癌患者的预后意义。

血清抗p53抗体在临床上用作结直肠癌的肿瘤标志物。然而，其在转移性结直肠癌（mCRC）患者中的预后意义仍然不清楚。KRAS状态可能会影响宿主针对肿瘤进展的免疫反应。在本研究中，我们调查了血清抗p53在野生型KRAS和突变KRAS的mCRC患者中的全身预后的意义。